You can buy or sell Xencor and other stocks, options, ETFs, and crypto commission-free!
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. Read More The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
52 Week High
52 Week Low
Seeking AlphaMay 10
Xencor, Inc. CEO Bassil Dahiyat on Q1 2019 Results - Earnings Call Transcript
Xencor, Inc. (NASDAQ:XNCR) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Charles Liles - Associate Director & Head of Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer Paul Foster - Senior Vice President & Chief Medical Officer John Kuch - Senior Vice President of Finance & Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Jaffray Jonathan Chang - SVP Leerink Eileen Maysek - Cantor Fitzgerald Sh...
Expected Aug 5, After Hours